What's in Assistance Publique - Hôpitaux de Paris's pipeline?

Assistance Publique - Hôpitaux de Paris has 368 drugs in our index: 76 marketed, 0 filed, 106 in Phase 3, 102 in Phase 2, 84 in Phase 1.

Which companies overlap with Assistance Publique - Hôpitaux de Paris's portfolio?

Top competitors by shared drug class: Pfizer, Sanofi, GlaxoSmithKline, Amgen, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/assistance-publique-h-pitaux-de-paris.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Assistance Publique - Hôpitaux de Paris — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assistance Publique - Hôpitaux de Paris pipeline: 76 marketed, 0 filed, 106 Phase 3, 102 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

76 marketed 0 filed 106 Phase 3 102 Phase 2 84 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Novel strategy Aspirin	Novel strategy Aspirin	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)	Cardiovascular; Pain management; Inflammation
Usual dose adjustment of enoxaparin	Usual dose adjustment of enoxaparin	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III)	Cardiovascular
Hydrea® (hydroxyurea )	Hydrea® (hydroxyurea )	marketed	Antimetabolite; ribonucleotide reductase inhibitor	Ribonucleotide reductase	Oncology; Hematology
Aspirin and clopidogrel / Prasugrel	Aspirin and clopidogrel / Prasugrel	marketed	Antiplatelet agent (dual therapy combination)	COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)	Cardiovascular
Conversion at day 7 ± 3 Prograf® to Advagraf®	Conversion at day 7 ± 3 Prograf® to Advagraf®	marketed
Placebo Formula 515	Placebo Formula 515	marketed
Tocilizumab, Abatacept	Tocilizumab, Abatacept	marketed
Mycophenolate mofetil,methotrexate	Mycophenolate mofetil,methotrexate	marketed
MEOPA	MEOPA	marketed			Oncology
Botulinum Toxin A (Botox )	Botulinum Toxin A (Botox )	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25); acetylcholine release machinery	Neurology; Dermatology; Aesthetics
14-day antibiotic therapy	14-day antibiotic therapy	marketed
during one week for the active treatments	during one week for the active treatments	marketed

Therapeutic area mix

Oncology · 28
Cardiovascular · 22
Other · 17
Immunology · 15
Infectious Disease · 10
Infectious Diseases · 4
Neurology · 4
Anesthesiology · 3
Cardiovascular; Pain management; Inflammation · 3
Immunology / Infectious Disease · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 14 shared drug classes
Sanofi · 11 shared drug classes
GlaxoSmithKline · 9 shared drug classes
Amgen · 8 shared drug classes
Hoffmann-La Roche · 8 shared drug classes
Pfizer Inc. · 7 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
Hospices Civils de Lyon · 6 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Assistance Publique - Hôpitaux de Paris:

Cite this brief

Drug Landscape (2026). Assistance Publique - Hôpitaux de Paris — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/assistance-publique-h-pitaux-de-paris. Accessed 2026-05-18.